VASCULAR-PERMEABILITY FACTOR (VPF, VEGF) IN TUMOR BIOLOGY

被引:777
作者
SENGER, DR [1 ]
VANDEWATER, L [1 ]
BROWN, LF [1 ]
NAGY, JA [1 ]
YEO, KT [1 ]
YEO, TK [1 ]
BERSE, B [1 ]
JACKMAN, RW [1 ]
DVORAK, AM [1 ]
DVORAK, HF [1 ]
机构
[1] HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115
关键词
VASCULAR PERMEABILITY FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR; ENDOTHELIAL CELLS;
D O I
10.1007/BF00665960
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular permeability factor (VPF), also known as vascular endothelial growth factor (VEGF), is a multifunctional cytokine expressed and secreted at high levels by many tumor cells of animal and human origin. As secreted by tumor cells, VPF/VEGF is a 34-42 kDa heparin-binding, dimeric, disulfide-bonded glycoprotein that acts directly on endothelial cells (EC) by way of specific receptors to activate phospholipase C and induce [Ca2+]i transients. Two high affinity VPF/VEGF receptors, both tyrosine kinases, have thus far been described. VPF/VEGF is likely to have a number of important roles in tumor biology related, but not limited to, the process of tumor angiogenesis. As a potent permeability factor, VPF/VEGF promotes extravasation of plasma fibrinogen, leading to fibrin deposition which alters the tumor extracellular matrix. This matrix promotes the ingrowth of macrophages, fibroblasts, and endothelial cells. Moreover, VPF/VEGF is a selective endothelial cell (EC) growth factor in vitro, and it presumably stimulates EC proliferation in vivo. Furthermore, VPF/VEGF has been found in animal and human tumor effusions by immunoassay and by functional assays and very likely accounts for the induction of malignant ascites. In addition to its role in tumors, VPF/VEGF has recently been found to have a role in wound healing and its expression by activated macrophages suggests that it probably also participates in certain types of chronic inflammation. VPF/VEGF is expressed in normal development and in certain normal adult organs, notably kidney, heart, adrenal gland and lung. Its functions in normal adult tissues are under investigation.
引用
收藏
页码:303 / 324
页数:22
相关论文
共 89 条
[21]  
CORDONCARDO C, 1990, LAB INVEST, V63, P832
[22]  
COSTANTINI V, 1991, CANCER RES, V51, P349
[23]  
DAMSKY CH, 1992, CURR OPIN CELL BIOL, V4, P772
[24]   PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].
DANO, K ;
ANDREASEN, PA ;
GRONDAHLHANSEN, J ;
KRISTENSEN, P ;
NIELSEN, LS ;
SKRIVER, L .
ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266
[25]   THE FMS-LIKE TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR [J].
DEVRIES, C ;
ESCOBEDO, JA ;
UENO, H ;
HOUCK, K ;
FERRARA, N ;
WILLIAMS, LT .
SCIENCE, 1992, 255 (5047) :989-991
[26]   CELLULAR AND VASCULAR MANIFESTATIONS OF CELL-MEDIATED-IMMUNITY [J].
DVORAK, HF ;
GALLI, SJ ;
DVORAK, AM .
HUMAN PATHOLOGY, 1986, 17 (02) :122-137
[27]  
DVORAK HF, 1984, CANCER RES, V44, P3348
[28]  
DVORAK HF, 1979, JNCI-J NATL CANCER I, V62, P1459
[29]  
DVORAK HF, 1987, LAB INVEST, V57, P673
[30]  
DVORAK HF, 1979, J IMMUNOL, V122, P166